ORPHAN DRUGS: WHAT FACTORS IMPACT THE PRICE IN FRANCE?

被引：0
|
作者：
De Joannis, P. E. [1 ]
Borget, I [2 ]
机构：
[1] Paris Saclay Univ, Chatenay Malabry, France
[2] Univ Paris Sud, Fac Pharm, GRADES, Villejuif, France
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PNS137
引用
收藏
页码：S784 / S785
页数：2
相关论文
共 50 条
  • [1] PRICE LIFE CYCLE MANAGEMENT OF ORPHAN DRUGS IN FRANCE
    Lebreton, C.
    Avot, D.
    Morand, F.
    Laigle, V
    Troubat, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A660 - A660
  • [2] FROM VALUE TO PRICE: WHAT SHOULD BE THE PATH FOR ORPHAN DRUGS?
    Ethgen, O.
    Hutchings, A.
    Rollet, P.
    Standaert, B.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A31 - A31
  • [3] The impact of early phase price agreements on prices of orphan drugs
    Mark Nuijten
    Philippe Van Wilder
    [J]. BMC Health Services Research, 21
  • [4] The impact of early phase price agreements on prices of orphan drugs
    Nuijten, Mark
    Van Wilder, Philippe
    [J]. BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [5] ASSOCIATION BETWEEN DISEASE PREVALENCE, DRUG PRICE AND ASMR FOR ORPHAN DRUGS IN FRANCE
    Korchagina, D.
    Toumi, M.
    Pliez, A.
    Millier, A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A597 - A597
  • [6] Access and price of cancer drugs: What is happening in France?
    Grande, Mathilde
    Fernandez, Judith
    Putzolu, Jade
    Stanel, Sorin
    Galbraith, Margaret
    Belorgey, Chantal
    Albin, Nicolas
    Guillevin, Loic
    d'Andon, Anne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] COMPARATIVE ANALYSIS OF HTA DECISIONS, PRICE AND REIMBURSEMENT LEVEL OF ORPHAN DRUGS IN FRANCE AND ITALY
    Korchagina, D.
    Tavella, F.
    Remuzat, C.
    Kornfeld, A.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A539 - A540
  • [8] ORPHAN DRUGS VERSUS ULTRA-ORPHAN DRUGS: PRICE COMPARISON IN ENGLAND
    Chachoua, L.
    Hanna, E.
    Zhou, J.
    Dussart, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S107 - S107
  • [9] Estimating the budget impact of orphan drugs in Sweden and France 2013–2020
    Adam Hutchings
    Carina Schey
    Richard Dutton
    Felix Achana
    Karolina Antonov
    [J]. Orphanet Journal of Rare Diseases, 9
  • [10] PRICE NEGOTIATIONS FOR ORPHAN DRUGS IN GERMANY
    Ecker, T.
    Bot, D.
    Campion, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A601 - A601
12345